Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Call Transcript

Anne-Marie Li-Kwai-Cheung: Sure. Well, the first clinical trial sites are Australia and UK with more coming. And to your question about what we expect to get from the volunteer study? Well, the volunteer study has been designed to enable us to most rapidly achieve doses patients that we would expect to see target engagement. And so it’s really designed for efficiency and speed. So, the healthy volunteer study will inform progress in the patient study and also of course safety and tolerability.

Paul Bolno: If you think about it the goal is to get very quickly to the first low-dose cohort, in the patient arm which is where we modeled to anticipate initially engaging target. So there’s a combination of how quickly, can we enroll and establish both safety and PK and tie that over to our preclinical modeling on PD, which is translated across multiple clinical programs to date. And to be able to affirm how do we get quickly to starting in a patient cohort, where we would expect to anticipate engaging targets. So this idea of kind of rapidly starting as opposed to building up in patients to get to a part where you eventually engage target, I think the team has done a really elegant job of bringing those pieces together to expedite getting to that proof of mechanism [indiscernible] as quickly as possible.

Q – Unidentified Analyst: Thanks. One more, if I may. Just on the milestones. Can you give us a sense of the cadence of the milestone payments from GSK for the A1AT program? Thanks.

Paul Bolno: Sure. I mean I think obviously, we can’t break it down. But we can say is, as we’ve said publicly, we have milestones for the program as we move through the clinic. Some of these are execution milestones and some of these are data inflection milestones. We anticipate milestone payments in 2023 and then 2024 and beyond. So that’s the most, I can say. But given the progress the team is making, I think it’s pretty clear to see a path to how we’re going to move through that cadence of potential milestones.

Q – Unidentified Analyst: Okay. Thanks for taking our questions.

Operator: Thank you. This does conclude the question-and-answer session of today’s program. I’d like to hand the program back to Dr. Paul Bolno for any further remarks.

Paul Bolno: Thank you all for joining the call this morning. I also want to thank our employees for their efforts towards delivering life-changing treatments for people battling devastating diseases. We have an exciting year on the horizon and we look forward to keeping you all updated on our progress. Have a great day.

Operator: Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.